andrew huberman on glp 1 Gwyneth Paltrow, & Retatrutide Andrew Huberman clarifies he is

Major trial launched to explore GLP-1 benefit in dementia A large-scale trial has been launched, with $100 million in backing, to explore whether lifestyle changes coupled with GLP-1 agonists or similar incretin therapies can reduce the risk of dementia

Whilst metreleptin monotherapy supports weight loss in obese individuals, it is not clinically meaningful with a mean 1.5 kg additional weight loss over 24 weeks noted in a previous trial [87]

Unapproved Status: IGF-1 DES is not approved by the FDA and is banned by international sports bodies

It enhances cognitive performance and reduces mental fatigue in individuals over 65 years and maintains healthy body fat and muscle composition in ageing individuals